Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Inclusion Criteria:

* A histologic diagnosis of cT1-T2 primary adenocarcinoma of the prostate prior to prostatectomy, with lymph node dissection at time of radical prostatectomy
* One or more of the following poor prognostic features:

  * tumor extension to seminal vesicle (pT3b) or bladder neck (T4)
  * established extracapsular extension (pT3a) and Gleason Score \>= 7
  * organ confined (pT2) with positive surgical margin and Gleason 8-10
  * preoperative PSA \> 20
* SWOG performance status 0-1
* PSA nadir of \<= 0.1 ng/ml up to 30 days prior to randomization. Patients must be randomized within 120 days after prostatectomy.
* Laboratory values (no more than 30 days before randomization) must be as follows:

  * Absolute granulocyte count: \>= 1,500/mm3
  * Platelets: \>= 100,000/mm3
  * Hemoglobin: \>= 10 g/dL
  * Serum Creatinine: \<= 1.5 x ULN
  * AST: \<= 1.5 x ULN
  * ALT: \<= 1.5 x ULN
  * Serum Calcium: \<= ULN
  * Total Bilirubin: \<=ULN
  * Plasma Phosphorus Level: \<= 6 mg/dl
* Patients with preoperative PSA \> 20 ng/mL must have a negative bone scan within 120 days of randomization
* A valid, signed, and witnessed informed consent by the patient

Exclusion Criteria:

* Small cell histology
* N1 disease or M1 disease
* Clinical T3 disease prior to prostatectomy
* Any other investigational therapy
* An active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment
* A history of cancer related hypercalcemia
* Uncontrolled heart failure
* Prior malignancy other than curatively treated squamous cell or basal cell carcinoma of the skin. If another malignancy has been treated and there is no evidence of relapse \> 5 years from the time of treatment, patients are eligible
* Androgen deprivation, chemotherapy, or radiation therapy to treat prostate carcinoma
* Current peripheral neuropathy of any etiology that is greater than Grade I